問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Infectious Disease

Division of General Internal Medicine

Digestive System Department

Division of Thoracic Medicine

Kaohsiung Municipal Ta-Tung Hospital

Division of Thoracic Medicine

更新時間：2023-09-19

莊政皓
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

101Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

莊政皓

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Thoracic Medicine

List

68Cases

2024-09-01 - 2029-02-05

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting4Sites

Recruiting4Sites

2022-11-01 - 2025-01-07

Phase III

Completed
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  • Condition/Disease

    Idiopathic Pulmonary Fibrosis

  • Test Drug

    BI 1015550

Participate Sites
8Sites

Not yet recruiting8Sites

2022-11-01 - 2025-04-14

Phase III

Completed
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

  • Condition/Disease

    Lung Diseases, Interstitial

  • Test Drug

    BI 1015550

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2024-10-25 - 2026-12-31

Phase I

Active
A Phase 1b Study to Evaluate HMBD-001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination with Cetuximab in Participants with Advanced Squamous Cell Cancers

  • Condition/Disease

    Cetuximab in Participants with Advanced Squamous Cell Cancers

  • Test Drug

    injective

Participate Sites
4Sites

Recruiting4Sites

2024-02-06 - 2029-08-30

Phase II

Active
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC

  • Condition/Disease

    NSCLC

  • Test Drug

    REGN3767 (Fianlimab) REGN2810 (Cemiplimab)

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2022-08-15 - 2024-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-12-01 - 2026-07-03

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-02-01 - 2028-02-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

1 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB